Directors' Report
Notes
This Directors' Report includes information that fulfils the requirements of a business review under the Companies Act 2006.
The Development Pipeline, Shareholder Information and Corporate Information sections are incorporated into this Directors' Report.
Details of the more significant risks to AstraZeneca are set out in the Principal risks and uncertainties section.
Many of our products are subject to litigation. Detailed information about material legal proceedings can be found in Note 25 to the Financial Statements.
References to prevalence of disease have been derived from a variety of sources and are not intended to be indicative of the current market or any potential market for AstraZeneca's pharmaceutical products since, among other things, there may be no correlation between the prevalence of a disease and the number of individuals who are treated for such a disease.
The glossary and the market definitions table are intended to provide a useful guide to terms and AstraZeneca's definitions of markets, as well as to acronyms and abbreviations, used in this Directors' Report.
In this Annual Report and Form 20-F Information, unless the context otherwise requires, 'AstraZeneca', 'the Group', 'we', 'us' and 'our' refer to AstraZeneca PLC and its consolidated entities and any reference to 'this Annual Report' is a reference to this Annual Report and Form 20-F Information.
Except as otherwise stated, references to days and/or months in this Annual Report are references to days and/or months in 2009.
Figures in parentheses in tables and in the Financial Statements are used to represent negative numbers.
- N.B.
- Image above shows members of the Senior Executive Team addressing questions from an audience of employees at a Town Hall meeting in Westborough, Massachusetts, US.
